Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 34.0
(-2.3%)
SEK 34.0
(-2.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 71.85 Million SEK | 144.3% |
| 2022 | 29.41 Million SEK | -5.59% |
| 2021 | 31.15 Million SEK | 37.13% |
| 2020 | 22.71 Million SEK | -15.73% |
| 2019 | 26.95 Million SEK | 150.32% |
| 2018 | 10.76 Million SEK | 87.17% |
| 2017 | 5.75 Million SEK | 6.78% |
| 2016 | 5.38 Million SEK | 100.45% |
| 2015 | 2.68 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 80.25 Million SEK | 11.69% |
| 2024 Q2 | 67.93 Million SEK | -15.35% |
| 2023 Q2 | 91.06 Million SEK | 241.71% |
| 2023 Q1 | 26.64 Million SEK | -9.39% |
| 2023 Q4 | 71.85 Million SEK | 67.54% |
| 2023 Q3 | 42.88 Million SEK | -52.91% |
| 2023 FY | 71.85 Million SEK | 144.3% |
| 2022 Q2 | 21.82 Million SEK | 11.3% |
| 2022 Q3 | 859.8 Million SEK | 3839.0% |
| 2022 Q1 | 19.61 Million SEK | -37.04% |
| 2022 FY | 29.41 Million SEK | -5.59% |
| 2022 Q4 | 29.41 Million SEK | -96.58% |
| 2021 FY | 31.15 Million SEK | 37.13% |
| 2021 Q2 | 20.95 Million SEK | -0.86% |
| 2021 Q3 | 22.9 Million SEK | 9.28% |
| 2021 Q4 | 31.15 Million SEK | 36.03% |
| 2021 Q1 | 21.13 Million SEK | -6.95% |
| 2020 Q4 | 22.71 Million SEK | 17.82% |
| 2020 FY | 22.71 Million SEK | -15.73% |
| 2020 Q3 | 19.28 Million SEK | 10.23% |
| 2020 Q2 | 17.49 Million SEK | -10.61% |
| 2020 Q1 | 19.56 Million SEK | -27.41% |
| 2019 Q3 | 20.66 Million SEK | 1.62% |
| 2019 FY | 26.95 Million SEK | 150.32% |
| 2019 Q1 | 14.16 Million SEK | 31.52% |
| 2019 Q2 | 20.33 Million SEK | 43.55% |
| 2019 Q4 | 26.95 Million SEK | 30.48% |
| 2018 Q4 | 10.76 Million SEK | 113.63% |
| 2018 FY | 10.76 Million SEK | 87.17% |
| 2018 Q1 | 4.07 Million SEK | -29.26% |
| 2018 Q2 | 5.83 Million SEK | 43.27% |
| 2018 Q3 | 5.04 Million SEK | -13.55% |
| 2017 Q2 | 2.85 Million SEK | 0.0% |
| 2017 Q3 | 14.47 Million SEK | 407.58% |
| 2017 Q4 | 5.75 Million SEK | -60.24% |
| 2017 FY | 5.75 Million SEK | 6.78% |
| 2017 Q1 | - SEK | -100.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | 5.38 Million SEK | 0.0% |
| 2016 FY | 5.38 Million SEK | 100.45% |
| 2015 FY | 2.68 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Active Biotech AB (publ) | 13.4 Million SEK | -436.194% |
| Biovica International AB (publ) | 34.76 Million SEK | -106.661% |
| Cantargia AB (publ) | 54.97 Million SEK | -30.708% |
| CombiGene AB (publ) | 4.15 Million SEK | -1628.826% |
| Cyxone AB (publ) | 4.69 Million SEK | -1430.677% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -889.669% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -421.727% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -439.091% |
| Fluicell AB (publ) | 8.91 Million SEK | -705.945% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -55.587% |
| Mendus AB (publ) | 51.22 Million SEK | -40.264% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -274.922% |
| I-Tech AB | 16.2 Million SEK | -343.382% |
| Intervacc AB (publ) | 21.68 Million SEK | -231.411% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -1292.982% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 42.047% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -2945.782% |
| OncoZenge AB (publ) | 1.69 Million SEK | -4128.958% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -107.641% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 85.099% |
| Lipum AB (publ) | 7.53 Million SEK | -853.171% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 32.595% |
| Ziccum AB (publ) | 6.38 Million SEK | -1024.765% |
| BioArctic AB (publ) | 139.5 Million SEK | 48.496% |
| Genovis AB (publ.) | 98.04 Million SEK | 26.719% |
| Camurus AB (publ) | 414.81 Million SEK | 82.679% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -17.102% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -345.803% |
| Aptahem AB (publ) | 8.99 Million SEK | -698.526% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -75.849% |
| Kancera AB (publ) | 17.97 Million SEK | -299.655% |
| Saniona AB (publ) | 86.08 Million SEK | 16.534% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -515.787% |
| AcouSort AB (publ) | 10.37 Million SEK | -592.33% |
| Xintela AB (publ) | 14.01 Million SEK | -412.665% |
| Abliva AB (publ) | 16.78 Million SEK | -328.163% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -521.056% |
| Amniotics AB (publ) | 10.54 Million SEK | -581.236% |
| 2cureX AB (publ) | 2.93 Million SEK | -2348.041% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -1523.362% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 95.411% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 93.941% |
| Biosergen AB | 5.08 Million SEK | -1312.979% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -169.021% |
| Corline Biomedical AB | 6.78 Million SEK | -958.33% |
| NextCell Pharma AB | 13.68 Million SEK | -424.872% |
| Nanologica AB (publ) | 79.32 Million SEK | 9.426% |
| LIDDS AB (publ) | 3.75 Million SEK | -1812.939% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 66.519% |
| BioInvent International AB (publ) | 90.45 Million SEK | 20.566% |
| SynAct Pharma AB | 51.83 Million SEK | -38.616% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -803.887% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -1283.076% |
| Alzinova AB (publ) | 9.33 Million SEK | -670.014% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -463.795% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 60.435% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -3905.017% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -288.504% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -1772.069% |
| Simris Alg AB (publ) | 148.93 Million SEK | 51.758% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -1.029% |